Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00315757 | Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 105 | Human Genome Sciences Inc.INDUSTRY | 4 | Aug 8, 2013 | clinicaltrials |
| NCT00094848 | Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) | completed | Phase 2 | — | Human Genome Sciences Inc.INDUSTRY | 1 | Aug 2, 2013 |
| NCT01914744 | Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL | unknown | Phase 2 | 82 | Fudan UniversityOTHER | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00507442 | Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients(EVOLUTION) | completed | Phase 1 / Phase 2 | 158 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 26, 2013 | clinicaltrials |
| NCT00842595 | Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas | completed | Phase 2 | 50 | French Innovative Leukemia OrganisationOTHER | 1 | Jul 24, 2013 | clinicaltrials |
| NCT00089154 | Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00003502 | Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003505 | Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00085345 | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | OncotherapeuticsINDUSTRY | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00112879 | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma | withdrawn | Phase 2 | 0 | The Cleveland ClinicOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT01118845 | Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 63 | SymBio PharmaceuticalsINDUSTRY | 2 | Jul 4, 2013 | clinicaltrials |
| NCT00002970 | 506U78 in Treating Patients With Refractory Hematologic Cancer | completed | Phase 2 | 148 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00079443 | FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2013 | clinicaltrials |
| NCT00776802 | GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma(GCS-100LE) | withdrawn | Phase 1 / Phase 2 | 0 | La Jolla Pharmaceutical CompanyINDUSTRY | 1 | Jun 25, 2013 | clinicaltrials |
| NCT00090493 | Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma | completed | Phase 2 / Phase 3 | 4 | University of ArkansasOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT01617213 | Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma(AMM-2011) | terminated | Phase 2 | 1 | University of VirginiaOTHER | 1 | Jun 21, 2013 | clinicaltrials |
| NCT00009984 | Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer | terminated | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT01238146 | Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00062244 | Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT01695590 | Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 40 | Prolexys PharmaceuticalsINDUSTRY | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00873457 | Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 16 | Daphne FriedmanOTHER | 1 | May 27, 2013 | clinicaltrials |
| NCT00126191 | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | terminated | Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | May 23, 2013 | clinicaltrials |
| NCT00801918 | Denileukine Diftitox for Relapsed ALCL | withdrawn | Phase 2 | 0 | Columbia UniversityOTHER | 1 | May 15, 2013 | clinicaltrials |
| NCT00715208 | Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma | completed | Phase 2 | 55 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Apr 29, 2013 | clinicaltrials |
| NCT01830478 | Lenalidomide Plus Rituximab (R) in Non Follicular NHL | unknown | Phase 2 | 44 | Gruppo Italiano Studio LinfomiOTHER | 1 | Apr 12, 2013 | clinicaltrials |
| NCT00968396 | Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 5, 2013 | clinicaltrials |
| NCT01686386 | Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma | unknown | Phase 1 / Phase 2 | 60 | Gruppo Italiano Studio LinfomiOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT01179490 | Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma | terminated | Phase 2 | 5 | SymBio PharmaceuticalsINDUSTRY | 1 | Mar 18, 2013 | clinicaltrials |
| NCT01148108 | Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma | completed | Phase 2 | 14 | TelikINDUSTRY | 1 | Mar 15, 2013 | clinicaltrials |
| NCT00412243 | Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients | completed | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 12, 2013 | clinicaltrials |
| NCT01806337 | CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma | completed | Phase 2 | 41 | University of GöttingenOTHER | 0 | Mar 7, 2013 | clinicaltrials |
| NCT01278602 | R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma | unknown | Phase 2 | 50 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT01667289 | Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma | terminated | Phase 2 | 4 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT01667302 | Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT01804127 | Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL | unknown | Phase 2 | 196 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT00661544 | Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients | completed | Phase 1 / Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00283985 | Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma | completed | Phase 2 | 40 | University Hospital, LimogesOTHER | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00536575 | Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 13 | SCRI Development Innovations, LLCOTHER | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00005811 | Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment | completed | Phase 2 | 77 | National Cancer Institute (NCI)NIH | 1 | Feb 21, 2013 | clinicaltrials |
| NCT00521560 | A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas(escZ-BEAM) | completed | Phase 2 | 28 | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbHOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00959686 | Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma(BENTLY) | completed | Phase 2 | 45 | French Innovative Leukemia OrganisationOTHER | 1 | Feb 12, 2013 | clinicaltrials |
| NCT00278382 | Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00016094 | S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 29, 2013 | clinicaltrials |
| NCT00452127 | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 26 | Genentech, Inc.INDUSTRY | 0 | Jan 28, 2013 | clinicaltrials |
| NCT00015912 | Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00064246 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder | completed | Phase 1 / Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00086944 | Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00401804 | Bortezomib-Dexamethasone-Doxorubicin-Study | completed | Phase 2 | 72 | Austrian Forum Against CancerOTHER | 2 | Jan 24, 2013 | clinicaltrials |
| NCT00005950 | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma | terminated | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00005982 | 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Aug 8, 2013source: clinicaltrials